

## Pharmacy Request for Prior Approval – A+KIDS: Antipsychotics-Keeping it Documented for Safety

## Beneficiaries 17 Years of Age and Younger

| Beneficiary Information  |   | _  |  |  |  |
|--|---|--|--|--|--|
| 1. Beneficiary Last Name:  |   |  |  |  |  |
| 3. Beneficiary ID #:   | 4. Beneficiary Date of  | Birth:   | 5  | Beneficiary Gender:                        |  |
| Prescriber Information   |   |  |  |  |  |
| 6. Prescriber Name:  |   | NPI i  | #:   |  |  |
| Mailing address:   |   |  | State: _   | ZIP:                                       |  |
| 7. Requester Contact Information:  |   |  |  |  |  |
| Name:  |   |  | Fax #: _   |  |  |
| Drug Information   |   |  |  |  |  |
| 8. Drug Name:  |   | gth:   |  | Per 30 Days:                               |  |
| 11. Length of Therapy:up to 30 days  |   |  |  |  |  |
| 12. Dose instructions:   |   |  |  |  |  |
| Clinical Information   |   |  |  |  |  |
| For Non-preferred Medications:   |   |  |  |  |  |
| 1 Failed 1 preferred drug? Yes N   |   |  |  |  |  |
| 1a Allergic Reaction 1b Drug   |   |  |  |  |  |
| 2 Previous episode of unacceptable s   | ide effect or therapeutic failu   | re. Please provide c   | linical information:   |  |  |
|  |   |  |  |  |  |
|  | lity or unique nationt circums  | stance as a contrain   | dication to preferred d  |  |  |
| 3 Clinical contraindication, co-morbid   |   |  |  |  |  |
| Please provide clinical information:   |   |  |  |  |  |
| Please provide clinical information:<br>4 Age specific indications. Please give  | patient age and explain:  |  |  |  |  |
| Please provide clinical information:4 Age specific indications. Please give 5 Unique clinical indication supported   | patient age and explain:<br>d by FDA approval or peer rev   | riewed literature.   |  |  |  |
| Please provide clinical information:4 Age specific indications. Please give 5 Unique clinical indication supporter Please explain and provide a general reference.   | patient age and explain:<br>d by FDA approval or peer reverence:  | iewed literature.  |  |  |  |
| <ul> <li>3 Clinical contraindication, co-morbid</li> <li>Please provide clinical information:</li> <li>4 Age specific indications. Please give</li> <li>5 Unique clinical indication supporte</li> <li>Please explain and provide a general refe</li> <li>6 Unacceptable clinical risk associate</li> </ul>  | patient age and explain:<br>d by FDA approval or peer reverence:  | iewed literature.  |  |  |  |
| Please provide clinical information:4 Age specific indications. Please give 5 Unique clinical indication supported Please explain and provide a general reference Unacceptable clinical risk associate   | patient age and explain:<br>d by FDA approval or peer reverence:  | iewed literature.  |  |  |  |
| Please provide clinical information:4 Age specific indications. Please give 5 Unique clinical indication supported Please explain and provide a general reference of the company of the clinical risk associate contents for ALL medications:  | e patient age and explain:<br>d by FDA approval or peer reverence:<br>d with therapeutic change. Pla  | riewed literature.   |  |  |  |
| Please provide clinical information:4 Age specific indications. Please give 5 Unique clinical indication supporter Please explain and provide a general refe 6 Unacceptable clinical risk associate Criteria for ALL medications: 7. What is the beneficiary's Primary Psycon  | e patient age and explain:<br>d by FDA approval or peer reverence:<br>d with therapeutic change. Pla  | iewed literature. ease explain:  |  | ler □ Bipolar Disorde                      |  |
| Please provide clinical information:4 Age specific indications. Please give 5 Unique clinical indication supporter Please explain and provide a general refe 6 Unacceptable clinical risk associate   Criteria for ALL medications: 7. What is the beneficiary's Primary Psyc   Disruptive Behavior Disorder   | e patient age and explain: d by FDA approval or peer reverence: d with therapeutic change. Plathing the province of | ease explain:  Attention Defic   | it-Hyperactivity Disord  | ler □ Bipolar Disorde                      |  |
| Please provide clinical information:4 Age specific indications. Please give 5 Unique clinical indication supporter Please explain and provide a general refe 6 Unacceptable clinical risk associate Criteria for ALL medications: 7. What is the beneficiary's Primary Psyc Disruptive Behavior Disorder Schizoaffective Disorder  | e patient age and explain: d by FDA approval or peer reverence: d with therapeutic change. Plain hiatric diagnosis?  Mood Disorder-NOS Schizophrenia  | ease explain:  Attention Defic  Any Pervasive I  Tourette's Sync   | it-Hyperactivity Disord<br>Development Disorder                  | ler ☐ Bipolar Disorde<br>☐ PTSD            |  |
| Please provide clinical information:4 Age specific indications. Please give 5 Unique clinical indication supporter Please explain and provide a general refe 6 Unacceptable clinical risk associate Criteria for ALL medications: 7. What is the beneficiary's Primary Psyc Disruptive Behavior Disorder Schizoaffective Disorder Schizoaffective Disorder 8. What is the beneficiary's target symptom 8.  | e patient age and explain: d by FDA approval or peer reverence: d with therapeutic change. Plain hiatric diagnosis?  Mood Disorder-NOS Schizophrenia  | ease explain:<br>Attention Defic<br>Any Pervasive I<br>Tourette's Sync   | it-Hyperactivity Disord<br>Development Disorder<br>drome □ Other | ler ☐ Bipolar Disorde<br>☐ PTSD            |  |
| Please provide clinical information:  4 Age specific indications. Please give  5 Unique clinical indication supporter  Please explain and provide a general refe  6 Unacceptable clinical risk associate  Criteria for ALL medications:  7. What is the beneficiary's Primary Psyc  □ Disruptive Behavior Disorder □  □ Schizoaffective Disorder □  8. What is the beneficiary's target sympt  □ Mania □ Oppositional                                | e patient age and explain: d by FDA approval or peer reverence: d with therapeutic change. Plain hiatric diagnosis?  Mood Disorder-NOS Schizophrenia om?  | ease explain:<br>Attention Defic<br>Any Pervasive I<br>Tourette's Sync   | it-Hyperactivity Disord<br>Development Disorder<br>drome         | ler ☐ Bipolar Disorde<br>☐ PTSD            |  |
| Please provide clinical information:  4 Age specific indications. Please give  5 Unique clinical indication supporter  Please explain and provide a general refe  6 Unacceptable clinical risk associate  Criteria for ALL medications:  7. What is the beneficiary's Primary Psyc  Disruptive Behavior Disorder    Schizoaffective Disorder    8. What is the beneficiary's target sympt  Mania Oppositional  9. Measurements: Obtained baseline Bl | e patient age and explain: d by FDA approval or peer reverence: d with therapeutic change. Plain hiatric diagnosis?  Mood Disorder-NOS Schizophrenia om?  | ease explain:  Attention Defice  Any Pervasive I  Tourette's Synce  Impuls   | it-Hyperactivity Disord<br>Development Disorder<br>drome         | ler ☐ Bipolar Disorde<br>☐ PTSD            |  |
| Please provide clinical information:4 Age specific indications. Please give 5 Unique clinical indication supporter Please explain and provide a general refe 6 Unacceptable clinical risk associate Criteria for ALL medications: 7. What is the beneficiary's Primary Psyc  | e patient age and explain: d by FDA approval or peer reverence: d with therapeutic change. Plain in the provided in | ease explain:  Attention Defic  Any Pervasive I  Tourette's Sync  Impuls  Other:   | iit-Hyperactivity Disord<br>Development Disorder<br>drome        | ler ☐ Bipolar Disorde☐ PTSD ☐ Irritability |  |
| Please provide clinical information:  4 Age specific indications. Please give  5 Unique clinical indication supporter  Please explain and provide a general refe  6 Unacceptable clinical risk associate  Criteria for ALL medications:  7. What is the beneficiary's Primary Psyc  Disruptive Behavior Disorder    Schizoaffective Disorder    8. What is the beneficiary's target sympt  Mania Oppositional  9. Measurements: Obtained baseline Bl | e patient age and explain: d by FDA approval or peer reverence: d with therapeutic change. Plain in the provided in | ease explain:  Attention Defic  Any Pervasive I  Tourette's Sync  Impuls  Other:   | it-Hyperactivity Disord Development Disorder drome               | ler  |  |
| Please provide clinical information:   | e patient age and explain: d by FDA approval or peer reverence: d with therapeutic change. Pla hiatric diagnosis? Mood Disorder-NOS Schizophrenia om?   | ease explain:  Attention Defice  Any Pervasive I  Impulse  Other:  pid Profile? Yes esting Glucose Monit   | it-Hyperactivity Disord Development Disorder drome               | ler  |  |
| Please provide clinical information:4 Age specific indications. Please give 5 Unique clinical indication supporter Please explain and provide a general refe 6 Unacceptable clinical risk associate Criteria for ALL medications: 7. What is the beneficiary's Primary Psyc  | e patient age and explain: d by FDA approval or peer reverence: d with therapeutic change. Pla hiatric diagnosis? Mood Disorder-NOS Schizophrenia om?   | ease explain:  Attention Defice  Any Pervasive I   | it-Hyperactivity Disord Development Disorder drome               | ler  |  |
| Please provide clinical information:4 Age specific indications. Please give 5 Unique clinical indication supporter Please explain and provide a general refe 6 Unacceptable clinical risk associate Criteria for ALL medications: 7. What is the beneficiary's Primary Psyc  | e patient age and explain: d by FDA approval or peer reverence: d with therapeutic change. Pla hiatric diagnosis? Mood Disorder-NOS Schizophrenia om?   | ease explain:  Attention Defice   Any Pervasive I   Tourette's Synce   Impulse   Other:    pid Profile? Yes esting Glucose Monite   Pending   ug Treatment? Pleas  | it-Hyperactivity Disord Development Disorder drome               | ler  |  |
| Please provide clinical information:   | e patient age and explain: d by FDA approval or peer reverence: d with therapeutic change. Plain in the province of the following reasons: patient age and explain: d by FDA approval or peer reverence: d with therapeutic change. Plain in the province of the following reasons: provinced   | ease explain:  Attention Defic Any Pervasive I Tourette's Sync Impuls Other:  pid Profile? Yes esting Glucose Monit Pending Ug Treatment? Pleas  | it-Hyperactivity Disord Development Disorder drome               | ler  |  |
| Please provide clinical information:4 Age specific indications. Please give 5 Unique clinical indication supporter Please explain and provide a general refe 6 Unacceptable clinical risk associate Criteria for ALL medications: 7. What is the beneficiary's Primary Psyc  | e patient age and explain: d by FDA approval or peer reverence: d with therapeutic change. Plothiatric diagnosis?  Mood Disorder-NOS Schizophrenia om?  | ease explain:  Attention Defice   Any Pervasive I   Tourette's Synce   Impulse   Other:    pid Profile? Yes esting Glucose Monite   Pending   ug Treatment? Please   ch improved   ch worse  | it-Hyperactivity Disord Development Disorder drome               | ler  |  |
| Please provide clinical information:4 Age specific indications. Please give 5 Unique clinical indication supporter Please explain and provide a general refe 6 Unacceptable clinical risk associate Criteria for ALL medications: 7. What is the beneficiary's Primary Psyc  | e patient age and explain: d by FDA approval or peer reverence: d with therapeutic change. Plothiatric diagnosis?  Mood Disorder-NOS Schizophrenia om?  | ease explain:  Attention Defice   Any Pervasive I   Tourette's Synce   Impulse   Other:    pid Profile? Yes  pisting Glucose Monite   Pending   ug Treatment? Please   ch improved   ch worse    Mild   M  | it-Hyperactivity Disord Development Disorder drome               | ler  |  |
| Please provide clinical information:   | e patient age and explain: d by FDA approval or peer reverence: d with therapeutic change. Plate in the provided and prov    | ease explain:  Attention Defice   Any Pervasive I   Tourette's Synce   Impulsi   Other:    pid Profile? Yes sting Glucose Monite   Pending   ug Treatment? Please   ch improved   ch worse   Mild   Mild | it-Hyperactivity Disord Development Disorder drome               | ler  |  |
| Please provide clinical information:4 Age specific indications. Please give 5 Unique clinical indication supporter Please explain and provide a general refe 6 Unacceptable clinical risk associate Criteria for ALL medications: 7. What is the beneficiary's Primary Psyc  | e patient age and explain: d by FDA approval or peer reverence: d with therapeutic change. Plothiatric diagnosis?  Mood Disorder-NOS Schizophrenia om?  | ease explain:  Attention Defice  | it-Hyperactivity Disord Development Disorder drome               | ler  |  |

\*Prescriber signature mandatory

I certify that the information provided is accurate and complete to the best of my knowledge, and I understand that any falsification, omission, or concealment of material fact may subject me to civil or criminal liability.